enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. AOL latest headlines, entertainment, sports, articles for business, health and world news.

  3. An experimental drug drove people to lose 23% of their body ...

    www.aol.com/news/novo-nordisk-next-generation...

    Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

  4. Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.

  5. Get the latest news, politics, sports, and weather updates on AOL.com.

  6. Fabre-Kramer Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Fabre-Kramer_Pharmaceuticals

    Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs.Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder, [1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.

  7. In Other News. Entertainment. Entertainment. Variety. Justin Baldoni files $250M lawsuit against New York Times over Blake Lively story. Entertainment. People.

  8. Horizon Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Horizon_Therapeutics

    Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. [3]

  9. Lexicon Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Lexicon_Pharmaceuticals

    Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. [2]